Verapamil and pulmonary hypertension.

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Pulmonary hypertension (PH) is a severe condition characterized by high blood pressure in the pulmonary arteries.
• Effective pharmacological treatments for PH are limited, necessitating research into novel therapeutic agents.

Purpose of the Study:

• To investigate the effects of verapamil, a calcium channel blocker, on hemodynamics in patients with pulmonary hypertension.

Main Methods:

• A study involving 12 patients diagnosed with pulmonary hypertension.
• Hemodynamic parameters including mean pulmonary artery pressure, right ventricular work performance, right atrial pressure, right ventricular end-diastolic pressure, pulmonary arteriolar resistance, cardiac index, and stroke volume were measured.
• The effects of verapamil administration were assessed.

Main Results:

• Verapamil administration resulted in a slight but statistically significant decrease in mean pulmonary artery pressure.
• A significant decrease in the work performance of the right ventricle was observed.
• No significant changes were noted in mean right atrial pressure, right ventricular end-diastolic pressure, pulmonary arteriolar resistance, cardiac index, or stroke volume.
• A wide variability in patient responses was observed.
• Some patients exhibited a marked negative inotropic effect, leading to an increase in pulmonary arteriolar resistance.

Conclusions:

• Verapamil demonstrates a modest beneficial effect on pulmonary artery pressure in some patients with pulmonary hypertension.
• However, the potential for negative inotropic effects and increased pulmonary vascular resistance in a subset of patients necessitates caution.
• Further research is warranted to identify patient subgroups who may benefit from verapamil and to understand the mechanisms behind adverse reactions.